title: The West Midlands epithelial ovarian cancer adjuvant therapy trial.
abstract: In a multicentre prospective randomized controlled trial, single agent cisplatinum was compared with whole abdomino-pelvic moving strip radiotherapy in the management of Stage IC-III epithelial ovarian cancer patients who had no macroscopic residual disease after primary surgery. Over a 6-year period 40 eligible patients were recruited, 15 of whom had Stage III disease. The overall 5-year survival was 60% with no significant survival difference between the treatment groups. Acute toxicity was common in both arms and six (11%) patients experienced significant long term disability.
authors.affiliation: West Midlands CRC Clinical Trials Unit, Queen Elizabeth Medical Centre, Birmingham, UK.
authors.forename: C W
authors.initials: CW
authors.lastname: Redman
authors.forename: J
authors.initials: J
authors.lastname: Mould
authors.forename: J
authors.initials: J
authors.lastname: Warwick
authors.forename: T
authors.initials: T
authors.lastname: Rollason
authors.forename: D M
authors.initials: DM
authors.lastname: Luesley
authors.forename: J
authors.initials: J
authors.lastname: Budden
authors.forename: F G
authors.initials: FG
authors.lastname: Lawton
authors.forename: G R
authors.initials: GR
authors.lastname: Blackledge
authors.forename: K K
authors.initials: KK
authors.lastname: Chan
mesh_terms: D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D011182:Postoperative Care; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D012086:Reoperation; D015996:Survival Rate; D013997:Time Factors
chemical_list: D002945:Cisplatin